Alnylam Third Quarter 2025 Financial Results

These sources provide a comprehensive overview of Alnylam Pharmaceuticals' robust performance during the third quarter of 2025, primarily detailing their financial and commercial successes, and pipeline updates. The company reported $851 million in combined net product revenues, representing 103% year-over-year growth, largely driven by the Trans-thyretin (TTR) franchise and the strong launch momentum of AMVUTTRA® for ATTR cardiomyopathy (ATTR-CM), which generated an estimated $300 million in quarterly revenue. Furthermore, the sources highlight progress in the pipeline, including the initiation of a Phase 1 trial for ALN-5288 targeting Alzheimer's disease and the ongoing Phase 3 trials for nucresiran and zilebesiran, an investigational hypertension treatment. Financial documents accompanying the earnings call also detail the company’s revenue reconciliation, increased 2025 guidance, and required regulatory disclosures regarding risk factors and tax changes.

There are no comments yet.

Please log in to write the first comment.